Effects of simvastatin on apoB metabolism and LDL subfraction distribution.

作者：AGaw, C JPackard, E FMurray, G MLindsay, B AGriffin, M JCaslake, B DVallance, A RLorimer, JShepherd · 发表于：Arteriosclerosis and Thrombosis A Journal of Vascular Biology · 年份：1993 · 被引用次数：67 · 研究领域：Lipoproteins and Cardiovascular Health、Cancer, Lipids, and Metabolism、Diabetes, Cardiovascular Risks, and Lipoproteins

Seven moderately hypercholesterolemic subjects were studied before and after 10 weeks of simvastatin therapy (20 mg/day). Therapy reduced low density lipoprotein (LDL) cholesterol by 39% (p < 0.001), whereas high density lipoprotein and very low density lipoprotein (VLDL) cholesterol were unchanged. Apolipoprotein (apo) B-containing lipoproteins were divided into VLDL1 (Sf 60-400), VLDL2 (Sf 20-60), intermediate density lipoprotein (IDL) (Sf 12-20), and LDL (Sf 0-12), and metabolic changes were sought in dual-tracer VLDL1 and VLDL2 turnover studies. VLDL1 apoB pool size was unaltered by therapy, as were its rates of synthesis, catabolism, and delipidation to VLDL2. Similarly, the VLDL2 apoB pool size was unchanged, but its metabolic fate was altered. The IDL pool size fell significantly (27%, p < 0.01) due entirely to an increased fractional catabolism of the lipoprotein. In our subjects, the circulating mass of LDL apoB decreased (49%, p < 0.01) primarily due to a reduction in its synthesis. Before thera...